| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR)
EIGR Technical Analysis
5
| As on 9th Jun 2023 EIGR STOCK Price closed @ 1.04 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 6.41 & Strong Sell for SHORT-TERM with Stoploss of 4.53 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EIGRSTOCK Price
| Open | 1.00 | Change | Price | % |
| High | 1.06 | 1 Day | 0.05 | 5.05 |
| Low | 0.93 | 1 Week | -0.08 | -7.14 |
| Close | 1.04 | 1 Month | 0.05 | 5.05 |
| Volume | 379600 | 1 Year | -4.38 | -80.81 |
| 52 Week High 9.74 | 52 Week Low 0.80 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| EIGR Daily Charts |
EIGR Intraday Charts |
Whats New @ Bazaartrend |
EIGR Free Analysis |
|
|
EIGR Important Levels Intraday
| RESISTANCE | 1.29 |
| RESISTANCE | 1.21 |
| RESISTANCE | 1.16 |
| RESISTANCE | 1.11 |
| SUPPORT | 0.97 |
| SUPPORT | 0.92 |
| SUPPORT | 0.87 |
| SUPPORT | 0.79 |
EIGR Forecast May 2024
| 4th UP Forecast | 4.51 |
| 3rd UP Forecast | 3.4 |
| 2nd UP Forecast | 2.71 |
| 1st UP Forecast | 2.02 |
| 1st DOWN Forecast | 0.06 |
| 2nd DOWN Forecast | -0.63 |
| 3rd DOWN Forecast | -1.32 |
| 4th DOWN Forecast | -2.43 |
EIGR Weekly Forecast
| 4th UP Forecast | 1.85 |
| 3rd UP Forecast | 1.59 |
| 2nd UP Forecast | 1.43 |
| 1st UP Forecast | 1.27 |
| 1st DOWN Forecast | 0.81 |
| 2nd DOWN Forecast | 0.65 |
| 3rd DOWN Forecast | 0.49 |
| 4th DOWN Forecast | 0.23 |
EIGR Forecast2024
| 4th UP Forecast | 18.9 |
| 3rd UP Forecast | 13.17 |
| 2nd UP Forecast | 9.63 |
| 1st UP Forecast | 6.09 |
| 1st DOWN Forecast | -4.01 |
| 2nd DOWN Forecast | -7.55 |
| 3rd DOWN Forecast | -11.09 |
| 4th DOWN Forecast | -16.82 |
Eiger BioPharmaceuticals Inc ( NASDAQ USA Symbol : EIGR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EIGR Business Profile
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California. Address: 2155 Park Boulevard, Palo Alto, CA, United States, 94306
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service